Comparing a new treatment with standard drugs for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that has spread to other parts of the body and is no longer controlled by hormone therapy.
- Your prostate cancer cells must show a protein called PSMA on PET scans.
- You must have had only one type of hormone therapy before that stopped working, and your doctor thinks another type might still help.
- Your cancer must be getting worse despite treatment, shown by rising PSA levels or new lesions on scans.
- You must be in generally good health with a performance status of 0 or 1, meaning you can carry out daily activities without help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests HRS-5041 in people with metastatic castration-resistant prostate cancer (prostate cancer that keeps growing despite lower testosterone). It aims to see if the drug can be given safely and whether it may help control the cancer after prior standard treatments.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This study tests a combination of two experimental drugs, HRS-2189 and HRS-5041, for men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The goal is to see if the combination is safe and effective in controlling tumor growth.
This trial tests a new drug called SRT-017 for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The drug targets a marker on cancer cells (PSMA) and may help slow the disease. The study will check if it is safe and effective.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Hear when a new PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.